13 / An Open-label Phase 2 Study of Carfilzomib plus Dexamethasone to Assess Tolerability and Adherence in Patients with Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers

2018 ◽  
Author(s):  
Fonseca Rafael
Keyword(s):  
Multiple Myeloma ◽  
Phase 2 ◽  
Open Label ◽  
Refractory Multiple Myeloma ◽  
Community Oncology ◽  
Phase 2 Study ◽  
Open Label Phase

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

2020 ◽  
Vol 21 (2) ◽  
pp. 207-221 ◽  
Author(s):  
Sagar Lonial ◽  
Hans C Lee ◽  
Ashraf Badros ◽  
Suzanne Trudel ◽  
Ajay K Nooka ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 2 ◽  
Open Label ◽  
Refractory Multiple Myeloma ◽  
Phase 2 Study ◽  
Open Label Phase

Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan

2019 ◽  
Vol 111 (1) ◽  
pp. 65-74 ◽  
Author(s):  
Kohmei Kubo ◽  
Mitsuo Hori ◽  
Kensuke Ohta ◽  
Hiroshi Handa ◽  
Kiyohiko Hatake ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 2 ◽  
Newly Diagnosed ◽  
Open Label ◽  
Phase 2 Study ◽  
Open Label Phase

A multicenter, randomized, open-label, phase 2 study of carfilzomib with or without ARRY-520 (filanesib) in patients with advanced multiple myeloma.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 8612-8612 ◽  
Author(s):  
Jeffrey A. Zonder ◽  
Noopur S. Raje ◽  
Emma Catherine Scott ◽  
Craig C. Hofmeister ◽  
Nikoletta Lendvai ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 2 ◽  
Open Label ◽  
Phase 2 Study ◽  
Open Label Phase
Sign in / Sign up

Export Citation Format

Share Document